Description

3-[(2,4-Dichlorobenzyloxy)Iminomethyl]Rifamycin Sv is a chemically modified derivative of the potent ansamycin antibiotic, rifamycin SV. This semisynthetic compound is engineered to enhance stability and target specificity for advanced pharmaceutical research and development. It is a critical intermediate and active pharmaceutical ingredient (API) for researchers and manufacturers developing next-generation antibacterial agents, particularly against resistant strains. Its unique structure makes it valuable for creating novel therapeutic formulations and conducting structure-activity relationship (SAR) studies.

Application

• Pharmaceutical Intermediate: Serves as a key building block in the synthesis of novel rifamycin-class antibiotics.
• Antibacterial Research: Used in microbiological and biochemical research to study mechanisms of bacterial RNA polymerase inhibition.
• API Development: Acts as an Active Pharmaceutical Ingredient in the formulation of targeted anti-infective medications.
• SAR Studies: Essential for Structure-Activity Relationship studies to optimize potency and reduce toxicity of antibiotic candidates.
• Reference Standard: Employed as a high-purity analytical standard in quality control laboratories for HPLC, LC-MS, or NMR analysis.
• Veterinary Medicine: Investigated for use in developing antibacterial treatments for animal health.

Basic Information

Product Name	3-[(2,4-Dichlorobenzyloxy)Iminomethyl]Rifamycin Sv
CAS No.	41970-84-7
Molecular Formula	C39H45Cl2N3O12
Molecular Weight	830.69 g/mol
Synonyms	3-[(2,4-Dichlorobenzyloxy)Iminomethyl]Rifamycin; Rifamycin SV, 3-[(2,4-dichlorobenzyloxy)iminomethyl]-; 3-[(O-(2,4-Dichlorobenzyl)oxime]rifamycin SV; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-Acetoxy-6,9,17,23-tetrahydroxy-3,5,15-trimethoxy-2,4,12,16,18,20,22-heptamethyl-1-oxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-8-carboxylic acid (2,4-dichlorobenzyl)oxime; Benzyoximerifamycin; Antibiotic CGP 4832; CGP-4832; CGP 4832
EINECS	Contact for details

Quality Control

Our 3-[(2,4-Dichlorobenzyloxy)Iminomethyl]Rifamycin Sv is manufactured under strict quality systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, IR and NMR for structural confirmation, and residual solvent analysis, to ensure it meets high-grade pharmaceutical standards. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting compliance with specified parameters. We support development projects with custom purity grades and analytical method support.

Storage

Preserve in a tightly closed container, protected from light. Store in a freezer at -20°C or below under an inert atmosphere (e.g., nitrogen or argon) to minimize oxidation and ensure long-term stability. Allow the sealed container to reach room temperature before opening to prevent condensation and moisture ingress. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	Reddish-brown to orange amorphous powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 95.0% (Standard Grade)
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Assay (on dried basis)	95.0% - 102.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.